Buntanetap for alzheimer disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 6 Oct 2016: Trial registered, NCT02925650
  2. 2 Mar 2017: Trial started, NCT02925650

The trials

NCT02925650: Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease

State
Completed
Phase
Phase 1 and Phase 2
People
18 taking part
Started
2 Mar 2017
Primary completion
10 Dec 2021
Arms
Low Dose, Medium Dose, High Dose
Results
Posted on the registry
Papers
doi:10.1101/2024.03.20.24304638, doi:10.1186/s13195-024-01490-z
  1. 6 Oct 2016: Trial registered
  2. 2 Mar 2017: Trial started
  3. 31 Dec 2021: Trial completed
  4. 9 May 2023: Trial results posted

How the status changed

  1. 16 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Also known as Posiphen.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.